Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
The plant is scheduled to come on stream in September 2024
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The first of four planned modules at the new plant is expected to come online by summer 2026
The facility is expected to become operational by FY2028-29
The revenues this quarter are in line with the outlook we envisaged for the year
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Subscribe To Our Newsletter & Stay Updated
